Comment
Author: Admin | 2025-04-28
With alcoholic liver disease. Use: Labeled IndicationsAcute gouty arthritis: Relief of signs and symptoms of acute gouty arthritis.Ankylosing spondylitis: Relief of signs and symptoms of ankylosing spondylitis.Arthritis: Relief of signs and symptoms of osteoarthritis and rheumatoid arthritis (RA).Bursitis/tendinitis of the shoulder: Relief of signs and symptoms of acute painful shoulder (acute subacromial bursitis/supraspinatus tendinitis). ContraindicationsHypersensitivity to sulindac or any component of the formulation; use in the setting of CABG surgery; history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs Dosage and AdministrationDosing: AdultAcute gouty arthritis: 200 mg twice daily for 7 days (maximum: 400 mg/day)Ankylosing spondylitis: 150 mg twice daily (maximum: 400 mg/day)Bursitis/tendinitis of the shoulder: 200 mg twice daily for 7 to 14 days (maximum: 400 mg/day)Osteoarthritis, rheumatoid arthritis: 150 mg twice daily (maximum: 400 mg/day)Dosing: GeriatricRefer to adult dosing. Use with caution; initiate dose at lower end of the dosing range.Dosing: PediatricJuvenile idiopathic arthritis (JIA): Limited data available: Children and Adolescents: Oral: 2 to 6 mg/kg/day in 2 divided doses maximum daily dose: 400 mg/day (APS 2016; Giannini 1995, Petty 2016)AdministrationAdminister with food or milk to decrease GI adverse effects. Dietary ConsiderationsMay administer with food, milk, or antacids to minimize GI upset. StorageStore at 20°C to 25°C (68°F to 77°F). Sulindac Images sulindac 150 mg sulindac 200 mg sulindac 200 mg sulindac 150 mg sulindac 200 mg sulindac 150 mg Drug Interactions5-Aminosalicylic Acid Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of 5-Aminosalicylic Acid Derivatives. Monitor therapyAcalabrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Monitor therapyAcemetacin: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Avoid combinationAgents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the antiplatelet effect of other Agents with Antiplatelet Properties. Monitor therapyAlcohol (Ethyl): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically,
Add Comment